药易购：10月23日召开董事会会议

Group 1 - The core point of the article is that Yaoyigou (SZ 300937) held its third meeting of the fourth board of directors on October 23, 2025, via telecommunication voting, discussing the proposal to amend certain company systems [1] - For the first half of 2025, Yaoyigou's revenue composition was as follows: pharmaceutical distribution (contract distribution + market comparison) accounted for 47.09%, pharmaceutical sales (direct procurement) accounted for 41.92%, pharmaceutical manufacturing and OEM business accounted for 8.55%, and other businesses accounted for 2.44% [1] - As of the time of reporting, Yaoyigou's market capitalization was 2.7 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have sold overseas licenses worth 80 billion USD this year, highlighting the hot secondary market in biomedicine while questioning the cold fundraising environment in the primary market [1]